Sida 1 från 301 resultat
OBJECTIVE
Loop diuretics and spironolactone are used in patients with hepatic edema, but they are sometimes associated with insufficient responses as well as adverse events. Tolvaptan, a vasopressin type 2 receptor antagonist, was approved for hepatic edema in 2013. A large-scale post-marketing
We report the case of an 80-year-old woman with postoperative congestive heart failure (CHF) complicated by Child-Pugh classification B liver cirrhosis and hepatic edema successfully treated with tolvaptan. The patient suffered from liver cirrhosis and underwent partial hepatectomy for a
To determine whether interstitial pulmonary edema occurs or not in experimental cirrhotic rats, male Sprague-Dawley rats were given carbon tetrachloride subcutaneously in order to induce liver cirrhosis. The percent lung water content of the cirrhotic rats increased to 79.1 +/- 0.7% compared to 77.4
OBJECTIVE
Liver cirrhosis represents the end stage of any chronic liver disease, and it is associated with hepatic edema such as ascites. Many patients with ascites do not respond to diuretic therapy or require administration of diuretics at high doses that can cause adverse events. This 7-day,
OBJECTIVE
Although it is an important treatment challenge to treat ascites with diuretic therapy, no objective markers have been established to assess improvement of ascites. However, change in bodyweight has been used as a marker of change in ascites volume. Thus, we evaluated the relationship
This large-scale post-marketing surveillance study (START study) evaluated the effectiveness and safety of tolvaptan in Japanese liver cirrhosis patients with hepatic edema in real-world clinical settings. Here, we present the final analysis outcomes.A OBJECTIVE
The relationship between the presence of villous edema (VE) in portal hypertensive enteropathy and clinical factors remains unclear. The aim of this study was to reveal the clinical factors related to VE in patients with liver cirrhosis (LC), and investigate the clinical significance of
OBJECTIVE
This study aimed to clarify the factors predictive of treatment response to tolvaptan (V2-receptor antagonist) for cirrhotic patients with hepatic edema in a real-world setting.
METHODS
In this retrospective, multicenter study, tolvaptan was orally administered at a dose of 7.5 mg once a
The combination of furosemide-amiloride was used in the management of fluid retention in 16 cirrhotic patients. The study lasted 60 days. In 15 out of the 16 patients a clinical response was observed, namely increased urinary volumen and reduction of abdominal girth. The body weight was reduced by a